InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | 2026-05-28 | SCHIMMEL PAUL | Director | Purchase | 100.0K | $0.50 | $50K | 779.1K | View ↗ | |
| 2026-02-04 | 2026-02-04 | Shukla Sanjay | Director & President and CEO | Sale | 3,745 | $0.98 | $4K | 153.6K | View ↗ | |
| 2026-02-04 | 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Sale | 1,558 | $0.98 | $2K | 37.3K | View ↗ | |
| 2026-02-04 | 2026-02-04 | DENYES NANCY | General Counsel | Sale | 1,118 | $0.98 | $1K | 33.1K | View ↗ | |
| 2025-10-09 | 2025-10-09 | SCHIMMEL PAUL | Director | Purchase | 318.0K | $0.94 | $299K | 1.41M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $190K-19.1% | $235K-33.4% | $353K-96.6% | $10.4M-0.7% | $10.5M |
| Research and development | $60.2M+10.8% | $54.4M+28.6% | $42.3M-1.2% | $42.8M+84.0% | $23.3M |
| General and administrative | $17.6M+27.7% | $13.8M+6.1% | $13.0M-7.2% | $14.0M+30.1% | $10.8M |
| Total operating expenses | $77.8M+14.2% | $68.1M+23.3% | $55.3M-2.7% | $56.8M+67.0% | $34.0M |
| Loss from operations | -$77.6M-14.3% | -$67.9M-23.7% | -$54.9M-18.3% | -$46.4M-36.4% | -$34.0M |
| Total other income (expense), net | $3.5M-10.0% | $3.9M-13.9% | $4.5M+326.2% | $1.1M+345.8% | $238K |
| Consolidated net loss | -$74.1M-15.8% | -$64.0M-27.0% | -$50.4M-11.1% | -$45.3M-34.2% | -$33.8M |
| Net loss (gain) attributable to noncontrolling interest in Pangu BioPharma Limited | $5K+600.0% | -$1K-112.5% | $8K+60.0% | $5K-44.4% | $9K |
| Net loss attributable to aTyr Pharma, Inc. | -$74.1M-15.8% | -$64.0M-27.1% | -$50.4M-11.1% | -$45.3M-34.3% | -$33.8M |
| Net loss per share - basic | -$800+7.0% | -$860+8.5% | -$940+41.3% | -$2K+9.6% | -$2K |
| Net loss per share - diluted | -$800+7.0% | -$860+8.5% | -$940+41.3% | -$2K+9.6% | -$2K |
| Shares used in computing net loss per share, basic | $92.99B+25.2% | $74.26B+38.5% | $53.61B+88.6% | $28.42B+48.9% | $19.08B |
| Shares used in computing net loss per share, diluted | $92.99B+25.2% | $74.26B+38.5% | $53.61B+88.6% | $28.42B+48.9% | $19.08B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results - Slideshow
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript